Antibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [1]
- Immunocytochemistry [2]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-21288 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CLCA1 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- Recommended positive controls: A431. Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.
- Reactivity
- Human
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µL
- Concentration
- 1 mg/mL
- Storage
- Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Submitted references High chloride channel accessory 1 expression predicts poor prognoses in patients with rectal cancer receiving chemoradiotherapy.
Chen TJ, He HL, Shiue YL, Yang CC, Lin LC, Tian YF, Chen SH
International journal of medical sciences 2018;15(11):1171-1178
International journal of medical sciences 2018;15(11):1171-1178
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot using CLCA1 Polyclonal Antibody (Product # PA5-21288). Sample (30 µg of whole cell lysate). A: A431. 7.5% SDS PAGE. CLCA1 Polyclonal Antibody (Product # PA5-21288) diluted at 1:1,000.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescent analysis of CLCA1 in methanol-fixed A431 cells using a CLCA1 polyclonal antibody (Product # PA5-21288) at a 1:200 dilution.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescence analysis of methanol-fixed A431, using CLCA1 antibody (Product # PA5-21288) at 1:200 dilution.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 2 Representative immunohistochemical staining of CLCA1 expression in our validation cohort of rectal cancers. Cases with low expression (A) and high expression (B) of CLCA1 from tumor specimens before treatment were demonstrated respectively .